Research Interest: Fate Decisions of Embryonic Stem Cell, Induced Pluripotent Stem Cell (ESC/Ips): Pluripotency and Direct Lineage Specification to the Three Germ Layers.

Research Interest: Leptin Receptors (Lepr) are Expressed by Various Types of Stem Cells Including Mesenchymal Stem Cells, Hematopoietic Stem Cells, Embryonic Stem Cells and Induced Pluripotent Stem Cells. Leptin/Lepr Signaling is also a Central Regulator of Metabolism.

Dr. Monther AlAlwan is a scientist at the Stem Cell and Tissue Re-engineering Program (SCTRP), King Faisal Specialist Hospital and Research Centre, as well as an Associate professor at Alfaisal University, Riyadh Saudi Arabia. He holds M.Sc. and Ph.D. in Immunology from Dalhousie University (Halifax, Canada). Dr. AlAlwan conducted a 3-years postdoctoral fellowship studying signaling in immune cells at the University of Manitoba, Canada. During his graduate studies and postdoctoral fellowship, Dr. AlAlwan made substantial contribution in the immunology field, particularly his groundbreaking discovery that highlighted the significance of the dendritic cells in the immunological synapse. After joining the SCTRP in 2007, he shifted gear to study cancer, where he identified novel mechanisms that regulate cancer metastasis and chemoresistance. Currently, he is actively involved in dissecting the molecular pathways that regulate the function of cancer stem cells and how this related to chemoresistance and metastasis. Dr. AlAlwan is an author in 20 peer-reviewed publications, has delivered several invited lectures and is a regular reviewer for various international journals.   

Research Interest: Harnessed the Biological Principle that Pregnancy and Hormones Mimicking Pregnancy Induced Breast Cancer Prevention.  The Preventive Effect of Pregnancy is Mediated by the Induction of Differentiation of the Mammary Gland.  In Studies Performed in Humans, He has Found that During the Post-Menopausal Years the Breast of Both Parous and Nulliparous Women Contains Preponderantly Lob 1 that Differs Biologically By Exhibiting Different Susceptibility to Carcinogenesis, And Remodeling Of Chromatin That Emerges As Novel Marker For Defining The Concept Of Differentiation In The Adult Breast.  His Laboratory Has Studied The Genomic Profile Of Nulliparous And Parous Women In The Premenopausal And Postmenopausal Period And Find That There Are Genes Only Activated During The First Five Years After Pregnancy That May Contribute To The Increased Risk Experimented By Certain Women After Pregnancy And At The Same Time They Have Confirmed That Pregnancy Induces A Long Lasting Genomic Signature That Start After Pregnancy That Explain Its Preventive Effect. The Molecular Mechanism Related To Prevention Is Around The Chromatin Remodeling Process. Using The In Vitro In Vivo Model Developed In His Laboratory He Is Identifying Drugs That Can Control Chromatin Remodeling As A Preventive Strategy.

Research Interest: Nanotechnology, Bioanalytical chemistry, infectious disease diagnosis, cellular analysis

Research Interest: Actually Works as Young Researcher in Projects Regarding Genomics, Proteomics and Inflammatory Aspects of Human Breast Cancer and Chronic Diseases. 

Research Interest: Therapeutic Application of ES and Ips Cells.

Dr. Edgar Grinstein is a Principal Investigator at the Heinrich Heine University in Düsseldorf (Germany). He researches hematopoietic stem cells and progenitor cells, signal transduction, gene transcription regulation. He has more than 11 years of experience as Editor-In-Chief at SAGE Publications Inc. (USA) and Libertas Academica (New Zealand), and also serves as Deputy Editor-In-Chief for Baishideng Publishing Group (USA).

Raised in a family of researchers – both parents are PhD scientists - he received his PhD summa cum laude in Molecular Biology from the Humboldt University and the Max-Delbrück Center for Molecular Medicine in Berlin. He has published a number of papers in high-ranking journals and received a highly regarded Research Award from Dr.-Günther- and Imme-Wille-Foundation. Dr. Grinstein qualified as Professor in Molecular Medicine at the University of Düsseldorf in 2008 and is a Visiting Professor at the University of Latvia (Latvia, European Union) since 2010.  

Dr. Grinstein`s research in the field of hematopoietic stem and progenitor cells, funded by research grants from German Research Foundation (DFG) and José Carreras Leukämie-Stiftung (José Carreras Foundation), has focused on markers, signal transduction and transcriptional control. Among other important findings made, his research group provided new insights into the role of the prominent surface marker AC133/CD133 (Leukemia 2015; 29: 2208-2220), that is expressed on stem/progenitor cells in normal hematopoiesis as well as on tumor-initiating cells in certain hematological malignancies. The study analyzed the control of AC133/CD133 expression in hematopoietic stem/progenitor cells, and revealed the impact thereof on molecular network relevant to these cells.

Research Interest: hematopoietic stem cells and progenitor cells, cancer stem cells, stem cell markers, signal transduction, cell cycle control, regulation of apoptosis, gene transcription regulation

Grants: Principal Investigator of stem cell-related projects funded by German Research Foundation (DFG) and by José Carreras Leukämie-Stiftung (José Carreras Foundation)

URL: https://www.wjgnet.com/2218-6204/MemberDetail/42530

publications:

Grinstein, E., and H.-D. Royer. 1995. Multiple octamer-binding proteins are targets for the cell cycle regulated nuclear inhibitor I-92. DNA Cell Biol. 14: 493-500.

Grinstein, E., I. Weinert, B. Droese, M. Pagano, and H.-D. Royer. 1996. Cell cycle regulation of nuclear factor p92 DNA-binding activity by novel phase-specific inhibitors. J. Biol. Chem. 271: 9215-9222.

Bargou, R.C., C. Wagener, K. Bommert, W. Arnold, P.T. Daniel, M.Y. Mapara, E. Grinstein, H.-D. Royer, and B. Dörken. 1996. Blocking of transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J. Exp. Med. 183: 1205-1213.

Bargou, R.C., F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.-D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, and B. Dörken. 1997. Constitutive nuclear factor kappaB-RelA activation is required for proliferation and survival of Hodkin’s desease tumor cells. J. Clin. Invest. 12: 2961-2969.

Janke, J., K. Schlüter, B. Jandrig, M. Theile, K. Kölble, W. Arnold, E. Grinstein, A.  Schwartz, L.E. Schwarz, P.M. Schlag, B.M. Jockusch, and S. Scherneck. 2000. Suppression of tumoriginecity in breast cancer cells by the microfilament protein profilin1. J. Exp. Med. 191: 1675-1685.

Grinstein, E.,* F. Jundt, I. Weinert, P. Wernet, and H.-D. Royer. 2002. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21: 1485-1492.

Grinstein, E., P. Wernet, P.J. Snijders, F. Rösl, I. Weinert, W. Jia, R. Kraft, Ch. Schewe, M. Schwabe, S. Hauptmann, M. Dietel, Ch. Meijer, and H.-D. Royer. 2002. Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. J. Exp. Med. 196: 1067-1078.

Grinstein, E.,* Y. Shan, L. Karawajew, P.J. Snijders, C.J. Meijer, H.-D. Royer, and P. Wernet. 2006. Cell cycle controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation.  J. Biol. Chem. 281: 22223-22235.

Grinstein, E.,* Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet. 2007. Nucleolin regulates gene expression in CD34 positive hematopoietic cells. J. Biol. Chem. 282: 12439-12449.

Grinstein, E.,* and P. Wernet. 2007. Cellular signaling in normal and cancerous stem cells. Cell. Signal. 19: 2428-2433.
This was the most read article of the Journal Cell. Signal. from July 2007 till March 2008. Source: SCIENCEDIRECT TOP 25 HOTTEST ARTICLES

Wethkamp, N., H. Hanenberg, C. Suschek, W. Wetzel, S. Heikaus, E. Grinstein, U. Ramp, R. Engers, H. Gabbert, and C. Mahotka. 2011. DAXX-beta and DAXX-gamma: two novel splice variants of the transcriptional co-repressor DAXX. J. Biol. Chem. 19576-19588.

Grinstein, E.,* C. Mahotka, and A. Borkhardt. 2011. Rb and nucleolin antagonize in controlling human CD34 gene expression. Cell. Signal. 23: 1358-1365.

Bhatia, S., S. Reister, C. Mahotka, R. Meisel, A. Borkhardt, and E. Grinstein.* 2015. Control of AC133 / CD133 and impact on human hematopoietic progenitor cells through nucleolin. Leukemia. 29: 2208-2220.

Mahotka, C., S. Bhatia, J. Kollet, and E. Grinstein.* 2018. Nucleolin promotes execution of the hematopoietic stem cell gene expression program. Leukemia. 32: 1865–1868.

Reister, S., C. Mahotka, N. van den Höfel, and  E. Grinstein.* 2019. Nucleolin promotes Wnt signaling in human hematopoietic stem/progenitor cells. Leukemia. 33: 1052-1054.

Research Interest: During those Years She Extended her Initial Research Interests on Endothelial Progenitor Cell (EPC) Biology and their Potential use in Regenerative Medicine. 

Research Interest: Cancer Stem Cells, Ocular Stem Cells

Research Interest: Clinical Nephrology, Metabolic Syndrome, Hypertension, Inflammation

Research Interest: Clinical Pharmacology, Gastroenterology, Pharmaceutical Development, Drug Development, Colorectal Cancer, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease

Research Interest: Drug Discovery and Development.

Research Interest: Neurological Disability.

Research Interest: Embryonic Stem Cells, Pluripotency, Induced Pluripotent Cells, Differentiation, Endoderm, Beta Cell, Diabetes, Obesity, Adipose Tissue, Brown Fat, Endothelium, Oxidative Stress, Nitric Oxide, Peroxynitrite, Superoxide, Nanosensors.